IQVIA Logo
Contact Us
Olink-machine

Olink — Scalable, multiplexed biomarkers

Rules-Based Medicine, an IQVIA business, performs Olink testing to support efficiency and precision in your clinical trials.

Rules-Based Medicine — a leader in testing soluble proteins for 25 years — performs Olink testing to support efficiency and precision in your clinical trials. 

 

Olink’s proximity extension assay (PEA®) technology delivers the throughput you need without compromising specificity or scalability.

 

Whether you need a small panel of focused biomarkers or a comprehensive exploratory assessment, RBM has an Olink option to meet your needs.
RBM_OlinkBrochure_Final_Digital (3)-1

Proximity extension assay (PEA®) technology

RBM_OlinkBrochure_Final_Digital (3)-23

 

diagram1The Olink PEA technology employs a dual-recognition approach using antibody pairs labeled with complementary DNA oligonucleotides. 

RBM_OlinkBrochure_Final_Digital (3)-2

 

diagram2

When the antibody pair binds to the target protein, the oligonucleotides are brought into proximity and hybridize, creating a unique DNA barcode for each protein.

RBM_OlinkBrochure_Final_Digital (3)-4

 

Iconography_Finals_Color_BarcodeThis DNA barcode is then extended and amplified by polymerase chain reaction (PCR) and measured by quantitative PCR (qPCR) or next-generation sequencing (NGS).

Olink is well suited to:

RBM_OlinkBrochure_Final_Digital (3)-2Evaluate therapeutic effects

Accurately measure at baseline and after treatment to understand the dynamic changes associated with a therapeutic candidate.
RBM_OlinkBrochure_Final_Digital (3)-2Understand disease onset and mechanism of action

Certain biomarkers are present years before diagnosis. Olink can help identify the relevant proteomic changes.
RBM_OlinkBrochure_Final_Digital (3)-2Develop biomarker signatures

Explore HT measures thousands of proteins at once. Longitudinal studies can help you understand proteomic profiles for different diseases.
RBM_OlinkBrochure_Final_Digital (3)-2Identify drug targets

Disease-specific proteomic signatures can help identify potential drug targets.

Available Olink products

5400+ proteins from a single sample

  • High-throughput, scalable biomarker discovery and analysis 
  • Integrates with other omics data for a comprehensive picture 
  • Useful for identifying disease targets, pharmacokinetics, longitudinal and population-based studies 

Carefully selected biomarkers for a comprehensive view: 

Choose RBM for exceptional science and service excellence

handshakeService excellence

  • RBM is an Olink service provider 
  • Responsive client services team 
  • My Green Lab® – bronze certification 
  • Hands-on project managers who have experience working in the lab 
  • 20+ years of expertise in delivering high-quality results on a timeline that meets your requirements. 

Iconography_Finals_Color_Olink proteomics platformExceptional Science

  • Dual-recognition approach uses antibody pairs labeled with DNA oligonucleotides 
  • Hybridization creates a unique barcode that is amplified using PCR 
  • Readouts by qPCR or NGS based on platform 

icon_graphMeaningful insights

Disease-specific insights: 

  • Oncology 
  • Inflammation/Immunology 
  • Cardiovascular 

Broad biosignatures (Explore HT) 

  • Deeper understanding of biological pathways and multi-omics interactions 
  • Scalable without compromising quality